Clinical Efficacy of Sodium Deoxyribonucleate in the Treatment of Acute Respiratory Infections

Abstract

The aim of the study was to evaluate the effectiveness of sodium deoxyribonucleate (spray) in the treatment of patients with acute respiratory infections (ARI) in the outpatient setting. Materials and Methods: We conducted a randomized controlled clinical trial. The study included 112 patients aged from 18 to 73 years with an established diagnosis of ARI and a duration of symptoms of the disease no more than 48 hours. The investigational drug – a 0.25% solution of sodium deoxyribonucleate (SD) for external and topical use (spray bottle, 10 ml). Group 1 included 54 patients who received SD: 2 intranasal doses into each nostril every 1-1.5 hours during the first days of the onset of the ARI symptoms; then - 2 doses into each nostril 3 times per day against the background of symptomatic therapy for 5 days. Symptomatic therapy included decongestants, antipyretics, mucolytics and antitussives (if necessary). Group 2 included 58 patients who received only symptomatic therapy. Medical examination was performed daily for 5 days. Results: Including a 0.25% SD spray solution in the ARI treatment regimen effectively affects the dynamics of the ARI symptoms. SD in the treatment scheme from the first day allows eliminating the main ARI symptoms much faster and more efficiently than the standard treatment regimen; in particular, recovery is accelerated by 2-3 days. Complex therapy including SD causes a 3-fold increase in the level of sIgA in the nasal mucosa of patients on the fifth day of treatment, which indicates a pronounced immunomodulating effect of this intervention, a potential reduction in the risk of complications and recurrence of viral diseases.

Keywords

• acute respiratory infections
• secretory immunoglobulin A
• squamous epithelium
• symptomatic therapy